AQST
$4.11
Aquestive Therapeutics, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of b...
Recent News
Aquestive Therapeutics Targets Q3 Anaphylm Resubmission After FDA CRL Flags Human Factors, PK Data
Aquestive Therapeutics (NASDAQ:AQST) executives used the Citizens Life Sciences Conference to outline the company’s path forward after receiving a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for Anaphylm, its oral film epinephrine product candidate for serious allergic
Aquestive Therapeutics Targets Q3 Anaphylm FDA Resubmission After CRL, Details Launch Plans at Leerink Conf
Aquestive Therapeutics (NASDAQ:AQST) executives used a presentation at the Leerink Global Healthcare Conference to outline the company’s strategic priorities, provide an update on its lead program Anaphylm following a recent FDA complete response letter (CRL), and discuss commercial planning, financ
Aquestive Therapeutics Q4 Earnings Call Highlights
Aquestive Therapeutics (NASDAQ:AQST) executives used the company’s fourth-quarter 2025 earnings call to outline a path forward for Anaphylm, its orally delivered epinephrine product candidate, following a Complete Response Letter (CRL) from the U.S. Food and Drug Administration. Management reiterate
Aquestive Therapeutics Inc (AQST) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Legal ...
Aquestive Therapeutics Inc (AQST) reports a 10% revenue increase in Q4 2025, while navigating significant legal expenses and preparing for Anaphylm's market launch.
Aquestive Therapeutics, Inc. Q4 2025 Earnings Call Summary
Moby summary of Aquestive Therapeutics, Inc.'s Q4 2025 earnings call